| Type 2 Diabetes Mellitus |
1 |
1 |
| Hospital |
0 |
0.99 |
| SGLT2 Inhibitor |
0 |
0.39 |
| Hypoglycemia |
0 |
0.38 |
| Coronary Artery Disease (CAD) |
0 |
0.31 |
| Cardiovascular Risk Management |
0 |
0.29 |
| Antiretroviral Therapy for HIV Infection |
0 |
0.28 |
| Heart Failure (HF) |
0 |
0.28 |
| Medical Life |
0 |
0.28 |
| Nucleoside Reverse Transcriptase Inhibitors |
0 |
0.27 |
| Pain Management |
0 |
0.26 |
| DPP-4 Inhibitors |
0 |
0.23 |
| Arrhythmia |
0 |
0.22 |
| Blood |
0 |
0.22 |
| Heart |
0 |
0.22 |
| Renal Disease |
0 |
0.19 |
| Hyperglycemia |
0 |
0.16 |
| Kidney |
0 |
0.16 |
| Kidney, Ureter, and Bladder |
0 |
0.16 |
| Match |
0 |
0.16 |
| Sulfonylureas |
0 |
0.16 |
| Asthma |
0 |
0.11 |
| Cerebrovascular Accident |
0 |
0.11 |
| Chronic Obstructive Pulmonary Disease |
0 |
0.11 |
| Clinician Health and Well-Being |
0 |
0.11 |
| Grant |
0 |
0.11 |
| Primary Care |
0 |
0.11 |
| Steroids |
0 |
0.11 |
| Chest Pain |
0 |
0.1 |
| Angina Pectoris |
0 |
0.08 |
| Hemoglobin A1c |
0 |
0.08 |
| Acute Coronary Syndrome |
0 |
0.06 |
| Artery |
0 |
0.06 |
| Cardiovascular disease |
0 |
0.06 |
| Clinical Research |
0 |
0.06 |
| Dorsum |
0 |
0.06 |
| Geriatrics |
0 |
0.06 |
| Health Administration |
0 |
0.06 |
| Health Care Reform |
0 |
0.06 |
| Hemoglobin |
0 |
0.06 |
| Minnesota |
0 |
0.06 |
| Outpatient Clinic |
0 |
0.06 |
| Pain |
0 |
0.06 |
| Pneumonia |
0 |
0.06 |
| Sepsis |
0 |
0.06 |
| Stress |
0 |
0.06 |
| Thorax |
0 |
0.06 |
| Transient Ischemic Attack |
0 |
0.06 |
| Urinary Tract Infection |
0 |
0.06 |